Loading
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
Düsseldorf · hospital | Germany | none recorded | 0 | 441 | 4,415 | none recorded | - |
Melbourne · research institute | Australia | none recorded | 0 | 342 | 5,286 | - | |
Barcelona · government | Spain | none recorded | 0 | 24 | 90 | none recorded | - |
Washington, DC · consortium | United States | none recorded | 0 | 10 | 220 | none recorded | - |
Ottawa · consortium | Canada | none recorded | 0 | 4 | 49 | none recorded | - |
Tübingen · consortium | Germany | none recorded | 0 | 4 | 11 | none recorded | - |
Montreal · government | Canada | none recorded | 0 | 3 | 8 | none recorded | - |
London · consortium | United Kingdom | none recorded | 0 | 0 | 0 | - | |
Tokyo · consortium | Japan | none recorded | 0 | 0 | 0 | none recorded | - |
Thornton Heath · consortium | United Kingdom | none recorded | 0 | not matched | - | none recorded | - |
Buenos Aires · government | Argentina | none recorded | 0 | not matched | - | none recorded | - |
Hualien · consortium | Taiwan | none recorded | 0 | not matched | - | none recorded | - |
Durham · university | United States | none recorded | 0 | not matched | - | none recorded | - |
Beijing · consortium | China | none recorded | 0 | not matched | - | none recorded | - |
Solihull · consortium | United Kingdom | none recorded | 0 | not matched | - | none recorded | - |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with T-cell prolymphocytic leukaemia but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.